List view / Grid view
A team from Trinity College Dublin have uncovered mechanisms that stem cells use to establish cellular identity, a process that will have potential in cancer and targeted treatments.
The researchers identified 1,068 transposable element-derived transcripts with the potential to produce tumour antigens that could serve as targets for new immunotherapies.
The new findings could pave the way to safer aspirin alternatives and might also have implications for improving cancer immunotherapies.
The natural process of removing damaged cell parts could present an alternative to antibiotics, especially where bacteria have become resistant to existing drugs.
US discovery opens the way to drugs that can prevent T cell therapies from losing their potency over time.
The activity of enzyme ATE1, as seen by US researchers, flags misfolded proteins for destruction and is enhanced by binding iron-sulphur clusters.
US researchers have invented a drug delivery technology that has implications for opioid epidemic, cancer treatment, rehabilitation care and more.
US researchers spotlight how p53, the most frequently mutated tumour suppressor gene, can be activated against cancer cells.
In this article Drug Target Review's Izzy Wood highlights three of the latest findings using lab automation techniques and technologies that aid scientists.
US researchers uncover the amino acid: arginine, that prompts genetic mutations in cancer cells.
Researchers found that ‘rational vaccinology’ increases potency by changing the structural location of antigens and adjuvants.
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
US research about immunological memory may help development of potential vaccines or immunotherapies for cancer and various inflammatory diseases.
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
